ADmit Therapeutics

Contact information
ADmit Therapeutic S.L.
Marta Barrachina
Calle Joan XIII, 10
Esplugues de Llobregat
Barcelona
605121564
Areas of activities
- A. Health Biotechnology
- Areas of activity
- Biomarkers
- In vitro diagnostics
- Therapeutic areas
- Central nervous system
- D. Services
- R&D services
- Bioinformatics
- Genomics
Commissions
ADmit Therapeutics, S.L. is a company spin-off from Bellvitge Biomedical Research Institute (IDIBELL), created in December 2017, and focused on the development and commercialization of a novel Alzheimer’s disease (AD) early detection technology.
Products and services
Our diagnostic test represents the determination of biomarkers non-related with β-amyloid nor tau. Therefore, our unique value proposition is that our test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA by next generation sequencing.
Areas of interest for future collaborations
Diagnostics, Drugs development and DNA sequencing platforms (next generation sequencing)
Biotech Sanitaria
Product / Service | Type | Therapeutic area | Development phase |
---|---|---|---|
ADmit Test | Biomarkers, Diagnostic | Sistema nervioso central | Clinical Validation |